MindBio Therapeutics CorpCanadian Securities Exchange:MBIO
- LAST PRICE0.0200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MBIO |
|---|---|---|
| 09:32 ET | 42000 | 0.02 |
| 10:33 ET | 80000 | 0.02 |
| 11:07 ET | 38000 | 0.02 |
| 12:44 ET | 39000 | 0.02 |
Oct 29, 2024
MindBio Reports a 72% Reduction in Severity of Depression Sustained Six Months After Treatment in Clinical Trials, from 1:01PM ET on Tuesday Oct 29, 2024 by Dow Jones
1:01PM ET on Tuesday Oct 29, 2024 by Dow Jones
Oct 24, 2024
Oct 22, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MindBio Therapeutics Corp | 2.7M | -6.4x | --- |
Manitex Capital Inc | 1.7M | -3.7x | +16.92% |
Silo Wellness Inc | 1.4M | -0.1x | --- |
Aequus Pharmaceuticals Inc | 1.3M | -0.5x | --- |
Intellipharmaceutics International Inc | 2.6M | -0.6x | --- |
Lucy Scientific Discovery Inc | 880.1K | -2.3x | --- |
Company Information
MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. It develops a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder. The underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.
Contact Information
- Headquarters
- 1055 West Georgia Street 1500 Royal CentreVANCOUVER, BC, Canada V6E 4N7
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7M |
|---|---|
Revenue (TTM) | $575.1K |
Shares Outstanding | 135.0M |
MindBio Therapeutics Corp does not pay a dividend. | |
Beta | --- |
EPS | $0.00 |
Book Value | $-0.04 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | 4.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -114.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
